26.07
-0.07 (-0.27%)
前收盘价格 | 26.14 |
收盘价格 | 26.11 |
成交量 | 605,456 |
平均成交量 (3个月) | 974,241 |
市值 | 1,207,163,520 |
预期市盈率 (P/E Forward) | 9.67 |
价格/销量 (P/S) | 1.74 |
股市价格/股市净资产 (P/B) | 1.57 |
52周波幅 | |
利润日期 | 28 Jul 2025 - 1 Aug 2025 |
营业毛利率 | -14.20% |
营业利益率 (TTM) | 15.77% |
稀释每股收益 (EPS TTM) | -2.15 |
季度收入增长率 (YOY) | 3.30% |
季度盈利增长率 (YOY) | -35.50% |
总债务/股东权益 (D/E MRQ) | 82.08% |
流动比率 (MRQ) | 2.40 |
营业现金流 (OCF TTM) | 189.39 M |
杠杆自由现金流 (LFCF TTM) | 163.38 M |
资产报酬率 (ROA TTM) | 3.90% |
股东权益报酬率 (ROE TTM) | -12.08% |
市场趋势
短期 | 中期 | ||
行业 | Drug Manufacturers - Specialty & Generic (US) | 看跌 | 混合的 |
Drug Manufacturers - Specialty & Generic (全球的) | 看跌 | 混合的 | |
股票 | Pacira BioSciences, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
分析师共识 | 3.0 |
内部交易活动 | NA |
价格波动 | -4.5 |
技术平均移动指标 | 0.0 |
技术振荡指标 | 2.0 |
平均 | 0.13 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. |
|
部门 | Healthcare |
行业 | Drug Manufacturers - Specialty & Generic |
投资方式 | Small Value |
内部持股比例 | 1.77% |
机构持股比例 | 107.04% |
52周波幅 | ||
目标价格波幅 | ||
高 | 65.00 (HC Wainwright & Co., 149.33%) | 购买 |
中 | 47.50 (82.20%) | |
低 | 30.00 (Needham, 15.08%) | 购买 |
平均值 | 47.50 (82.20%) | |
总计 | 2 购买 | |
平均价格@调整类型 | 25.70 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
Needham | 09 May 2025 | 30.00 (15.07%) | 购买 | 25.12 |
08 Apr 2025 | 32.00 (22.75%) | 购买 | 26.27 | |
HC Wainwright & Co. | 08 Apr 2025 | 65.00 (149.33%) | 购买 | 26.27 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合